Anti-TRAP Antibody (7N644) is a Rabbit antibody targeting TRAP. Anti-TRAP Antibody (7N644) can be used in IHC-P,IHC-Fr,IF.

IgG

7N644

Human

1. Western blot analysis of A431 cell lysate. Using TRAP (TMAB-13740) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
2. Paraformaldehyde-fixed, paraffin embedded Human Liver Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with TRAP Monoclonal Antibody, Unconjugated (TMAB-13740) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
3. Paraformaldehyde-fixed, paraffin embedded Human Lung; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with TRAP Monoclonal Antibody, Unconjugated (TMAB-13740) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.

IHC-P: 1:50-200; IHC-Fr: 1:50-200; IF: 1:50-200

Monoclonal

A synthesized peptide: human TRAP

Human

ACP5

Tartrate-resistant acid phosphatase type 5

Defects in ACP5 are the cause of spondyloenchondrodysplasia with immune dysregulation (SPENCDI) [MIM:607944]. A disease characterized by vertebral and metaphyseal dysplasia, spasticity with cerebral calcifications, and strong predisposition to autoimmune diseases. The skeletal dysplasia is characterized by radiolucent and irregular spondylar and metaphyseal lesions that represent islands of chondroid tissue within bone. Note=ACP5 inactivating mutations result in a functional excess of phosphorylated osteopontin causing deregulation of osteopontin signaling and consequential autoimmune disease.